|
1
|
Reck M, Popat S, Reinmuth N, De Ruysscher
D, Kerr KM and Peters S; ESMO Guidelines Working Group, :
Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 25 Suppl 3:iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wallach D: Cell death induction by TNF: A
matter of self control. Trends Biochem Sci. 22:107–109. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jackman D, Pao W, Riely GJ, Engelman JA,
Kris MG, Jänne PA, Lynch T, Johnson BE and Miller VA: Clinical
definition of acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Massarelli E, Varella-Garcia M, Tang X,
Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS and Wistuba II:
KRAS mutation is an important predictor of resistance to therapy
with epidermal growth factor receptor tyrosine kinase inhibitors in
non-small-cell lung cancer. Clin Cancer Res. 13:2890–2896. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Horssen R, Ten Hagen TL and Eggermont
AM: TNF-alpha in cancer treatment: Molecular insights, antitumor
effects, and clinical utility. Oncologist. 11:397–408. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen G and Goeddel DV: TNF-R1 signaling: A
beautiful pathway. Science. 296:1634–1635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arnott CH, Scott KA, Moore RJ, Robinson
SC, Thompson RG and Balkwill FR: Expression of both TNF-αlpha
receptor subtypes is essential for optimal skin tumour development.
Oncogene. 23:1902–1910. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McCoy MK and Tansey MG: TNF signaling
inhibition in the CNS: Implications for normal brain function and
neurodegenerative disease. J Neuroinflammation. 5:452008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beg AA and Baltimore D: An essential role
for NF-kappaB in preventing TNF-alpha-induced cell death. Science.
274:782–784. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jones DR, Broad RM, Madrid LV, Baldwin AS
Jr and Mayo MW: Inhibition of NF-kappaB sensitizes non-small cell
lung cancer cells to chemotherapy-induced apoptosis. Ann Thorac
Surg. 70:930–937. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mendelsohn J and Baselga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sethi G, Ahn KS, Chaturvedi MM and
Aggarwal BB: Epidermal growth factor (EGF) activates nuclear
factor-κB through IκBα kinase-independent but EGF receptor-kinase
dependent tyrosine 42 phosphorylation of IκBα. Oncogene.
34:54072015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Biswas DK, Cruz AP, Gansberger E and
Pardee AB: Epidermal growth factor-induced nuclear factor kappa B
activation: A major pathway of cell-cycle progression in
estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci
USA. 97:pp. 8542–8547. 2000; View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun L and Carpenter G: Epidermal growth
factor activation of NF-kappaB is mediated through IkappaBalpha
degradation and intracellular free calcium. Oncogene. 16:2095–2102.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao X, Fan W, Xu Z, Chen H, He Y, Yang G,
Yang G, Hu H, Tang S, Wang P, et al: Inhibiting tumor necrosis
factor-alpha diminishes desmoplasia and inflammation to overcome
chemoresistance in pancreatic ductal adenocarcinoma. Oncotarget.
7:81110–81122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang CY, Mayo MW and Baldwin AS Jr: TNF-
and cancer therapy-induced apoptosis: Potentiation by inhibition of
NF-kappaB. Science. 274:784–787. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim JY, Lee S, Hwangbo B, Lee CT, Kim YW,
Han SK, Shim YS and Yoo CG: NF-kappaB activation is related to the
resistance of lung cancer cells to TNF-alpha-induced apoptosis.
Biochem Biophys Res Commun. 273:140–146. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanaka K, Babic I, Nathanson D, Akhavan D,
Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, et al: Oncogenic
EGFR signaling activates an mTORC2-NF-κB pathway that promotes
chemotherapy resistance. Cancer Discov. 1:524–538. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin Y, Bai L, Chen W and Xu S: The
NF-kappaB activation pathways, emerging molecular targets for
cancer prevention and therapy. Expert Opin Ther Targets. 14:45–55.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Delhalle S, Deregowski V, Benoit V,
Merville MP and Bours V: NF-kappaB-dependent MnSOD expression
protects adenocarcinoma cells from TNF-alpha-induced apoptosis.
Oncogene. 21:3917–3924. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song L, Xiong H, Li J, Liao W, Wang L, Wu
J and Li M: Sphingosine kinase-1 enhances resistance to apoptosis
through activation of PI3K/Akt/NF-κB pathway in human non-small
cell lung cancer. Clin Cancer Res. 17:1839–1849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37 Suppl 4:S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brabender J, Danenberg KD, Metzger R,
Schneider PM, Park J, Salonga D, Hölscher AH and Danenberg PV:
Epidermal growth factor receptor and HER2-neu mRNA expression in
non-small cell lung cancer is correlated with survival. Clin Cancer
Res. 7:1850–1855. 2001.PubMed/NCBI
|
|
24
|
Repetto L, Gianni W, Aglianò AM and
Gazzaniga P: Impact of EGFR expression on colorectal cancer patient
prognosis and survival: A response. Ann Oncol. 16:15572005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bhargava R, Gerald WL, Li AR, Pan Q, Lal
P, Ladanyi M and Chen B: EGFR gene amplification in breast cancer:
Correlation with epidermal growth factor receptor mRNA and protein
expression and HER-2 status and absence of EGFR-activating
mutations. Mod Pathol. 18:1027–1033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Reddy BK, Lokesh V, Vidyasagar MS, Shenoy
K, Babu KG, Shenoy A, Naveen T, Joseph B, Bonanthaya R,
Nanjundappa, et al: Nimotuzumab provides survival benefit to
patients with inoperable advanced squamous cell carcinoma of the
head and neck: A randomized, open-label, phase IIb, 5-year study in
Indian patients. Oral Oncol. 50:498–505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cabanas R, Saurez G, Rios M, Alert J,
Reyes A, Valdes J, Gonzalez MC, Pedrayes JL, Avila M, Herrera R, et
al: Treatment of children with high grade glioma with nimotuzumab:
A 5-year institutional experience. MAbs. 5:202–207. 2013.
View Article : Google Scholar : PubMed/NCBI
|
